the role of intestinal flora dysbiosis in promoting the development of colorectal adenomatous polyps in patients with metabolism-associated fatty liver disease

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300078517

Enrollment

Unknown

Registered

2023-12-11

Start date

2024-01-01

Completion date

Unknown

Last updated

2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metabolic associated fatty liver disease

Interventions

Case series:NA

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: MAFLD patients undergoing colonoscopy.

Exclusion criteria

Exclusion criteria: ? MAFLD combined with other liver diseases: viral hepatitis, autoimmune liver disease, etc.; ? Acute infectious diseases; ? History of previous colorectal diseases: colorectal tumors, inflammatory bowel disease, etc.; ? Taking probiotics in the last month; ? Pregnant women; ? Those with incomplete information.

Design outcomes

Primary

Measure	Time frame
intestinal flora;short-chain fatty acid;	—

Countries

China

Contacts

Public ContactLiu Liu

The Sixth Affiliated Hospital, South China University of Technology, School of Medicine

405019875@qq.com+86 757 8121 0505

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026